Sara Sheikhbahaei, Ricardo Bello Martinez, Mark C Markowski, Mario A Eisenberger, Kenneth J Pienta, Diane Reyes, Mary Katherine Brosnan, Ergi Spiro, Rehab AbdAllah, Daniel P Holt, Robert F Dannals, Rudolf A Werner, Martin G Pomper, Michael A Gorin, Lilja B Solnes, Steven P Rowe
OBJECTIVE: The aims of this study were to investigate the utility of [18 F]F-Florastamin, a novel prostate-specific membrane antigen (PSMA)-targeted PET radiotracer with facile radiochemistry, relative to the conventional imaging for the detection of sties of disease and evaluate the effect of multi-timepoint imaging with [18 F]F-Florastamin PET on lesion detectability. METHODS: Eight prostate cancer patients with known or suspected recurrence who underwent [18 F]F-Florastamin PET/CT at 1-h and 2-h imaging time-points were included in this prospective pilot study...
March 1, 2023: Annals of Nuclear Medicine